Kronos Bio, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kronos Bio, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Kronos Bio, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$14.1M, a 55% increase year-over-year.
  • Kronos Bio, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$85.6M, a 28.2% increase year-over-year.
  • Kronos Bio, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$113M, a 15.4% increase from 2022.
  • Kronos Bio, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$133M, a 11.8% increase from 2021.
  • Kronos Bio, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$151M, a 70.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$85.6M -$14.1M +$17.3M +55% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$103M -$16.2M +$13.5M +45.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$116M -$30M -$3.72M -14.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$113M -$25.3M +$6.46M +20.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$119M -$31.4M +$882K +2.73% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$120M -$29.7M +$3.16M +9.61% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$123M -$26.2M +$10M +27.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$133M -$31.8M +$30.6M +49% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$164M -$32.3M +$1.35M +4.01% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$165M -$32.9M -$3.85M -13.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$161M -$36.3M -$10.2M -39% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$151M -$62.3M +$26.1M +29.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$177M -$33.6M +$6.11M +15.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$183M -$29.1M -$20.5M -239% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$163M -$26.1M -$19.1M -273% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$144M -$88.4M -$72.3M -449% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-23
Q3 2020 -$71.4M -$39.7M -$35.7M -890% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$35.7M -$8.58M -$5.07M -144% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$30.6M -$7M -$3.87M -123% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$26.8M -$16.1M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 -$4.01M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-18
Q2 2019 -$3.51M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-18
Q1 2019 -$3.13M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.